Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | CCR3 | P51677 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16226629 | 0.81 | GRIN2B (0.58) | MEN1KMT2ACCR3 | |
| SCHEMBL16759363 | 0.81 | SLC6A9 (0.46) | MEN1KMT2AOPRM1OPRD1ATM | |
| SCHEMBL84788 | 0.79 | OPRM1 (0.44) | MEN1KMT2AOPRM1OPRD1OPRK1 | |
| SCHEMBL15981158 | 0.79 | HRH3 (0.54) | OPRK1CCR3 | |
| SCHEMBL85392 | 0.79 | OPRM1 (0.48) | MEN1KMT2AOPRM1OPRD1OPRK1 | |
| SCHEMBL72670 | 0.79 | MEN1 (0.48) | MEN1KMT2AOPRM1OPRD1OPRK1 | |
| SCHEMBL14141067 | 0.79 | OPRM1 (0.44) | MEN1KMT2AOPRM1OPRD1OPRK1 | |
| SCHEMBL15166137 | 0.79 | OPRD1 (0.57) | MEN1KMT2AOPRD1 | |
| Hydrochloric Acid SCHEMBL3552812 | 0.78 | MEN1 (0.47) | MEN1KMT2AOPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL4159913 | 0.78 | OPRM1 (0.43) | MEN1KMT2AOPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140088081-A1 | Amino-Heterocyclic Compounds | PFIZER INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140088081-A1 | Amino-Heterocyclic Compounds | PFIZER INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140088081-A1 | Amino-Heterocyclic Compounds | PFIZER INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-8618117-B2 | Amino-heterocyclic compounds | PFIZER INC. (US) | 2013-12-31 | — | — | US | disclosed |
| EP-2389382-B1 | Amino-heterocyclic compounds used as pde9 inhibitors | PFIZER (US) | 2013-06-05 | — | — | EP | disclosed |
| EP-2389382-B1 | Amino-heterocyclic compounds used as pde9 inhibitors | PFIZER (US) | 2013-06-05 | — | — | EP | disclosed |
| US-20120329777-A1 | Amino-Heterocyclic Compounds | PFIZER INC. | 2012-12-27 | — | — | US | disclosed |
| US-20120329777-A1 | Amino-Heterocyclic Compounds | PFIZER INC. | 2012-12-27 | — | — | US | disclosed |
| US-20120329777-A1 | Amino-Heterocyclic Compounds | PFIZER INC. | 2012-12-27 | — | — | US | disclosed |
| US-8278295-B2 | Amino-heterocyclic compounds | PFIZER INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278295-B2 | Amino-heterocyclic compounds | PFIZER INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278295-B2 | Amino-heterocyclic compounds | PFIZER INC. (US) | 2012-10-02 | — | — | US | disclosed |
| EP-2389382-A1 | Amino-heterocyclic compounds used as pde9 inhibitors | Pfizer Inc. (US) | 2011-11-30 | — | — | EP | disclosed |
| US-8041687-B2 | Dynamic generation of XML Schema for backend driven data validation | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2011-10-18 | — | — | US | disclosed |
| US-20100190771-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190771-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190771-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2010-07-29 | — | — | US | disclosed |
| WO-2010084438-A1 | AMINO-HETEROCYCLIC COMPOUNDS USED AS PDE9 INHIBITORS | PFIZER INC. (US) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010084438-A1 | AMINO-HETEROCYCLIC COMPOUNDS USED AS PDE9 INHIBITORS | PFIZER INC. (US) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329777-A1 | Amino-Heterocyclic Compounds | PDE9A, PDE2A, PDE10A | MEN1 3122/4885KMT2A 1487/4885OPRM1 3328/4885 |
| US-20100190771-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PDE9A, PDE2A, PDE10A | MEN1 3122/4885KMT2A 1487/4885OPRM1 3328/4885 |
| US-20140088081-A1 | Amino-Heterocyclic Compounds | PDE9A, PDE2A, PDE10A | MEN1 3122/4885KMT2A 1487/4885OPRM1 3328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.